{{chembox
| Verifiedfields = changed
| verifiedrevid = 477499263
| ImageFile = Mafosfamide.svg
| ImageSize = 175
| ImageAlt = Skeletal formula
| ImageFile1 = Mafosfamide-3D-balls.png
| ImageSize1 = 230
| ImageAlt1 = Ball-and-stick model
| IUPACName=2-<nowiki/>{(2-[bis(2-chloroethyl)amino]-2-oxido-1,3,2-oxazaphosphinan-4-yl}thio)ethanesulfonic acid
| OtherNames=2-<nowiki/>{[2-[bis(2-chloroethyl)amino]-2-oxo-1-oxa-3-aza-2Î»<sup>5</sup>-phosphacyclohex-4-yl}sulfanyl]ethanesulfonic acid

| Section1 = {{Chembox Identifiers
| InChI = 1/C9H19Cl2N2O5PS2/c10-2-4-13(5-3-11)19(14)12-9(1-6-18-19)20-7-8-21(15,16)17/h9H,1-8H2,(H,12,14)(H,15,16,17)/t9-,19-/m1/s1
| InChIKey = PBUUPFTVAPUWDE-AYLIAGHABO
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C9H19Cl2N2O5PS2/c10-2-4-13(5-3-11)19(14)12-9(1-6-18-19)20-7-8-21(15,16)17/h9H,1-8H2,(H,12,14)(H,15,16,17)/t9-,19-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PBUUPFTVAPUWDE-AYLIAGHASA-N
| CASNo_Ref = {{cascite|changed|??}}
| CASNo = 88859-04-5 
| PubChem = 104746
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 16736958   
| SMILES = O=P1(N[C@@H](CCO1)SCCS(O)(=O)=O)N(CCCl)CCCl
| MeSHName = Mafosfamide
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5970HH9923
  }}

| Section2 = {{Chembox Properties
| Formula = C<sub>9</sub>H<sub>19</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>5</sub>PS<sub>2</sub>
| MolarMass = 401.269 g/mol
| Appearance =
| Density =
| MeltingPt =
| BoilingPt =
| Solubility =
  }}

| Section3 = {{Chembox Hazards
| MainHazards =
| FlashPt =
| AutoignitionPt =
  }}
}}

'''Mafosfamide''' ([[International Nonproprietary Name|INN]]) is an oxazaphosphorine ([[cyclophosphamide]]-like) [[alkylating antineoplastic agent|alkylating agent]] under investigation as a [[chemotherapeutic]].  It is metabolized by [[cytochrome P450]] into [[4-hydroxycyclophosphamide]], which is then converted into [[aldophosphamide]], which, in turn yields the [[cytotoxic]] [[metabolite]]s [[phosphoramide mustard]] and [[acrolein]].<ref> Ludeman SM. The chemistry of the metabolites of cyclophosphamide. Curr Pharm Des. 1999 Aug;5(8):627-43. {{PMID|10469895}}</ref>

Several [[Clinical trial#Phase I|Phase I]] [[clinical trial|trials]] have been completed.<ref>{{cite web | url = http://www.clinicaltrials.gov/ct/show/NCT00062881?order=1 | title = Intrathecal Mafosfamide | accessdate = 2007-07-13 | date = August 21, 2006 | publisher = U.S. [[National Institutes of Health]] | work = ClinicalTrials.gov}} ClinicalTrials.gov Identifier NCT00062881.</ref><ref>{{cite web | url =http://www.clinicaltrials.gov/ct/show/NCT00031928?order=2 | title = Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors | accessdate = 2007-07-13 | date = February 20, 2007 | publisher = U.S. [[National Institutes of Health]] | work = ClinicalTrials.gov}} ClinicalTrials.gov Identifier NCT00031928.</ref>

==References==
{{Reflist}}

{{Chemotherapeutic agents}}




[[Category:Experimental cancer drugs]]
[[Category:Oxazaphosphinans]]
[[Category:Phosphorodiamidates]]
[[Category:Nitrogen mustards]]
[[Category:Organochlorides]]
[[Category:Thioethers]]
[[Category:Sulfonic acids]]


{{antineoplastic-drug-stub}}